VK2735 could be ‘significant value driver’ for Viking, says H.C. Wainwright

After Viking Therapeutics announced the initiation of the Phase 2 VENTURE trial of the dual GLP-1/GIP agonist VK2735 in patients with obesity, H.C. Wainwright noted that Viking recently announced results from its SAD/MAD Phase 1 trial that the firm calls “a very promising initial look at VK2735’s potential in obesity.” The firm, which believes VK2735 is “becoming increasingly well-positioned in the space” and could “become a significant value driver for the company.” The firm reiterates a Buy rating and $33 price target on Viking shares.